Compare · FLGT vs ILMN
FLGT vs ILMN
Side-by-side comparison of Fulgent Genetics Inc. (FLGT) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLGT and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $41.04B, about 71.0x FLGT ($578.1M).
- ILMN has been more active in the news (8 items in the past 4 weeks vs 1 for FLGT).
- ILMN has more recent analyst coverage (25 ratings vs 9 for FLGT).
- Company
- Fulgent Genetics Inc.
- Illumina Inc.
- Price
- -
- -
- Market cap
- $578.1M
- $41.04B
- 1M return
- -9.11%
- -
- 1Y return
- -13.05%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2000
- News (4w)
- 1
- 8
- Recent ratings
- 9
- 25
Fulgent Genetics Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest FLGT
- Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- CFO and Treasurer Kim Paul covered exercise/tax liability with 2,087 shares, decreasing direct ownership by 0.58% to 356,543 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 0.49% to 885,952 units (SEC Form 4) to satisfy tax liability
- Chief Scientific Officer Gao Hanlin sold $32,885 worth of shares (1,673 units at $19.66), decreasing direct ownership by 0.17% to 986,117 units (SEC Form 4) (withholding tax)
- President and COO Xie Jian sold $41,809 worth of shares (2,127 units at $19.66), decreasing direct ownership by 0.59% to 359,924 units (SEC Form 4) to satisfy withholding obligation
- Chief Executive Officer Hsieh Ming covered exercise/tax liability with 2,949 shares, decreasing direct ownership by 0.33% to 890,344 units (SEC Form 4) (withholding obligation)
- CFO and Treasurer Kim Paul covered exercise/tax liability with 1,168 shares, decreasing direct ownership by 0.32% to 358,630 units (SEC Form 4) to satisfy tax liability
- President and COO Xie Jian sold $23,747 worth of shares (1,193 units at $19.91), decreasing direct ownership by 0.33% to 362,051 units (SEC Form 4) to satisfy withholding tax
- Chief Scientific Officer Gao Hanlin sold $18,691 worth of shares (939 units at $19.91), decreasing direct ownership by 0.09% to 987,790 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Fulgent Genetics Inc.
Latest ILMN
- Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- SEC Form 8-K filed by Illumina Inc.
- Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Illumina releases SpliceAI2 to help advance rare disease research
- SEC Form 4 filed by Illumina Inc.
- SEC Form SCHEDULE 13G filed by Illumina Inc.
- Director Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)
- Director Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)
- Chief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)
- SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)